New eye drug seeks to halt leading cause of blindness
NCT ID NCT05953012
Summary
This first-in-human study tested the safety of a new eye injection called PMC-403 for wet age-related macular degeneration (AMD), a major cause of vision loss. It involved 17 participants with wet AMD whose vision was still declining despite standard treatments. The main goal was to find a safe dose for future testing by giving participants single or multiple injections and monitoring them closely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASAN Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Seoul National University Bundang Hospital
Seoul, Bundang-gu, 13620, South Korea
-
Yeungnam University
Daegu, Nam-gu, 42415, South Korea
-
Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
Conditions
Explore the condition pages connected to this study.